Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery
Primary Purpose
Esophageal Anastomotic Stricture
Status
Unknown status
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
Oral Prednisone
Sponsored by
About this trial
This is an interventional prevention trial for Esophageal Anastomotic Stricture
Eligibility Criteria
Inclusion Criteria:
- The patients who develop the severe esophageal strictures from 28 days after esophageal surgery
Exclusion Criteria:
- Pulmonary and cardiac disorders
- Liver and renal dysfunctions
- Allergic
- Pregnancy
- infectious disease
- Unsuitable condition
Sites / Locations
- Nagasaki UniversityRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Patients after esophageal surgery
Arm Description
Oral Prednisone for 12 weeks
Outcomes
Primary Outcome Measures
Number of participants with treatment-related adverse events as assessed by Clavien-Dindo Classification
Incidence of Adverse Events of Grade 3 and Grade 4 of CTCAE v4.0
physical conditions, clinical laboratory abnormalities, and ECG abnormalities
Incidence of treatment discontinuations, modifications, and interruptions due to adverse events
Secondary Outcome Measures
Rate of re-strictures at 85 postoperative days
Number of participants with endoscopic classification of strictures before intervention
Dysphagia score
Session of the dilatation
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02703376
Brief Title
Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery
Official Title
Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
March 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
March 2019 (Anticipated)
Study Completion Date
October 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nagasaki University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is safety and proof-of-concept study for oral prednisolone in the treatment of esophageal stricture after esophageal surgery. The patients who develop the severe esophageal strictures from 28 days after esophageal surgery are included. Primary outcomes are Safety and Success rate of this treatment.
Detailed Description
Esophageal strictures are common complications after surgery and aggressive endoscopic submucosal dissection (ESD) for early-stage esophageal cancer and adenocarcinoma. However, patients, who develop esophageal strictures after extensive operations, usually develop refractory strictures. Although there are several treatments for refractory strictures, their utility is limited.
Yamaguchi and colleagues have developed new treatments using oral prednisolone. They have shown the safety and potential efficacy to prevent esophageal strictures after ESD. However, the efficacy and safety of oral prednisolone is not evaluated to esophageal stricture after esophageal surgery.
This study is safety and proof-of-concept study for oral prednisolone in the treatment of esophageal stricture after esophageal surgery. The patients who develop the severe esophageal strictures from 28 days after esophageal surgery are included. Primary outcomes are Safety and Success rate of this treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Anastomotic Stricture
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients after esophageal surgery
Arm Type
Other
Arm Description
Oral Prednisone for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Oral Prednisone
Other Intervention Name(s)
prednisolone
Intervention Description
Intakes of Oral Prednisone for 12 weeks after balloon dilations
Primary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by Clavien-Dindo Classification
Time Frame
for 12 weeks after the intervention
Title
Incidence of Adverse Events of Grade 3 and Grade 4 of CTCAE v4.0
Description
physical conditions, clinical laboratory abnormalities, and ECG abnormalities
Time Frame
for 12 weeks after the intervention
Title
Incidence of treatment discontinuations, modifications, and interruptions due to adverse events
Time Frame
for 12 weeks after the intervention
Secondary Outcome Measure Information:
Title
Rate of re-strictures at 85 postoperative days
Time Frame
for 12 weeks after the intervention
Title
Number of participants with endoscopic classification of strictures before intervention
Time Frame
before the intervention
Title
Dysphagia score
Time Frame
for 12 weeks after the intervention
Title
Session of the dilatation
Time Frame
for 12 weeks after the intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patients who develop the severe esophageal strictures from 28 days after esophageal surgery
Exclusion Criteria:
Pulmonary and cardiac disorders
Liver and renal dysfunctions
Allergic
Pregnancy
infectious disease
Unsuitable condition
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kobayashi Shinichiro, M.D.
Phone
+81958197316
Email
skobayashi1980@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Kobayashi Shinichiro
Phone
+81958197316
Email
skobayashi1980@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kobayashi Shinichiro
Organizational Affiliation
Department of Surgery Nagasaki University Graduate School of Biomedical Sciences
Official's Role
Study Director
Facility Information:
Facility Name
Nagasaki University
City
Nagasaki
ZIP/Postal Code
852-8501
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kobayashi Shinichiro, M.D.
Phone
+81958197316
Email
shinichirokobayashi@nagasaki-u.ac.jp
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
21492854
Citation
Yamaguchi N, Isomoto H, Nakayama T, Hayashi T, Nishiyama H, Ohnita K, Takeshima F, Shikuwa S, Kohno S, Nakao K. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc. 2011 Jun;73(6):1115-21. doi: 10.1016/j.gie.2011.02.005. Epub 2011 Apr 14.
Results Reference
background
PubMed Identifier
25386058
Citation
Kobayashi S, Kanai N, Ohki T, Takagi R, Yamaguchi N, Isomoto H, Kasai Y, Hosoi T, Nakao K, Eguchi S, Yamamoto M, Yamato M, Okano T. Prevention of esophageal strictures after endoscopic submucosal dissection. World J Gastroenterol. 2014 Nov 7;20(41):15098-109. doi: 10.3748/wjg.v20.i41.15098.
Results Reference
background
Learn more about this trial
Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery
We'll reach out to this number within 24 hrs